Executive summary
Novo Nordisk's next-generation weekly obesity therapy, CagriSema, failed to demonstrate non-inferiority to Eli Lilly's tirzepatide in a late-stage trial. The 809-patient, 84-week study produced average weight loss of 23% for CagriSema versus 25.5% for tirzepatide. Markets reacted swiftly: Novo Nordisk shares plunged 16.5% to their lowest level since June 2021, while Eli Lilly's stock rose approximately 4.3% on the same day. UBS analysts earlier trimmed peak sales expectations for this class, and the latest outcome intensifies investor scrutiny of Novo's growth prospects in GLP-era obesity therapeutics.
Key data points (clear, quotable)
- Trial size: 809 participants
- Treatment duration: 84 weeks
- CagriSema mean weight loss: 23%
- Tirzepatide mean weight loss: 25.5%
- Market reaction: Novo Nordisk shares fell 16.5%; Lilly shares rose ~4.3%
- UBS peak sales revision (earlier): from $80bn to $75bn for GLP-1 category by 2032
These figures form the core comparative baseline investors and analysts will cite in valuations and forecasts.
Trial outcome and clinical context
CagriSema is a combination weekly injection that pairs cagrilintide (an amylin analogue) with semaglutide (a GLP-1 analogue). The trial’s primary objective was to demonstrate non-inferiority for body-weight reduction versus tirzepatide at 84 weeks. The study did not meet that primary endpoint: average weight loss on CagriSema was 23% versus 25.5% on tirzepatide. Initial market expectations had centered on roughly 25% weight loss for CagriSema, making the 23% outcome a notable shortfall against investor assumptions.
Novo Nordisk has said it will pursue additional data, including studies testing a higher CagriSema dose, while also maintaining a regulatory submission already filed in the United States based on earlier evidence. The company projects potential market entry timelines that could include approval and launch activity later this year and early next year for different CagriSema programs.
Market reaction and financial impact
The market response was immediate and significant:
- Novo Nordisk's shares declined 16.5% to the lowest level since June 2021, contributing to an almost 60% decline over the past 12 months.
- Eli Lilly’s shares increased by about 4.3% on the day of the announcement.
Analyst houses had already adjusted long-term peak sales assumptions for the GLP-1 weight-loss category prior to this result; UBS reduced its 2032 peak sales forecast from $80 billion to $75 billion in January. The latest data point increases downside risk to Novo’s growth projections that depended on CagriSema as a competitive upgrade to semaglutide-based therapies.
Competitive positioning
- CagriSema: combination of an amylin analogue (cagrilintide) plus semaglutide; designed to augment satiety and suppress appetite.
- Competing product (Eli Lilly): tirzepatide demonstrated 25.5% mean weight loss in the same comparative window.
The trial result reduces CagriSema’s positioning as a clear competitive upgrade over tirzepatide. Investors will evaluate whether a higher-dose program or label advantages can restore differentiation.
Implications for investors and analysts
- Revenue trajectory: Novo Nordisk had relied on pipeline launches (CagriSema, Wegovy pill) to offset slowing growth; the CagriSema outcome increases the risk of downward revisions to near- and medium-term revenue and profit forecasts.
- Valuation risk: sharp share-price moves signal material reassessments of Novo’s forward cash flows tied to obesity drugs.
- Competitive moat: Eli Lilly’s tirzepatide advantage in this head-to-head comparison strengthens Lilly’s commercial positioning in obesity therapies and may accelerate market share gains.
- Clinical development: success of a higher-dose CagriSema study or differentiated label claims will be a key upside scenario; failure to produce superior data would likely leave semaglutide-combination programs more vulnerable.
Investors should update models to reflect: (1) probability-weighted launch scenarios for CagriSema, (2) potential downward revisions to peak sales for GLP-class products, and (3) near-term margin and guidance risk for Novo Nordisk.
Regulatory and product timeline
Novo Nordisk has submitted CagriSema to the US regulator on the basis of prior trials and is pursuing further dose-exploration studies. The company has indicated the potential for regulatory activity later this year and for a market introduction early next year, contingent on additional data and regulator decisions.
What to watch next (actionable signals)
- Results from higher-dose CagriSema studies and timing of their readouts
- US regulatory timelines and any requests for additional data
- Revisions to sell-side consensus forecasts for Novo Nordisk and category-wide peak sales
- Competitive trial updates or label expansions from Eli Lilly and other GLP-class developers
- Near-term guidance updates from Novo Nordisk on sales and margins
Investor takeaway
The CagriSema 84-week head-to-head result (23% vs. 25.5% for tirzepatide) is a material clinical and commercial data point that has already driven pronounced market re-pricing. For professional investors and analysts, the immediate tasks are to re-adjust probability-weighted launch scenarios, monitor follow-on dose studies, and reassess Novo Nordisk’s share of the long-term obesity therapeutics market.
